AdvisorNet Financial Inc trimmed its position in shares of Quest Diagnostics Incorporated () by 13.7% during the 3rd quarter, reports.

Source: https://www.americanbankingnews.com/2023/12/25/advisornet-financial-inc-sells-122-shares-of-quest-diagnostics-incorporated-nysedgx.html

Bank of America downgraded Quest Diagnostics from a “buy” rating to a “neutral” rating and cut their price target for the company from $166.00 to $148.00 in a report on Tuesday, May 2nd.

Source: https://www.etfdailynews.com/2023/06/27/exchange-traded-concepts-llc-has-633000-holdings-in-quest-diagnostics-incorporated-nysedgx/

Creative Financial Designs Inc. ADV boosted its holdings in shares of Quest Diagnostics by 3,310.0% during the 1st quarter.

Source: https://www.dailypolitical.com/2023/10/28/fjarde-ap-fonden-fourth-swedish-national-pension-fund-has-3-66-million-position-in-quest-diagnostics-incorporated-nysedgx.html

DnB Asset Management AS owned approximately 0.07% of Quest Diagnostics worth $11,580,000 at the end of the most recent reporting period.

Source: https://www.dailypolitical.com/2023/09/16/dnb-asset-management-as-lowers-stake-in-quest-diagnostics-incorporated-nysedgx.html

Finally, Morgan Stanley reissued an “equal weight” rating and issued a $145.00 price objective on shares of Quest Diagnostics in a research report on Thursday, August 3rd.

Source: https://www.americanbankingnews.com/2023/10/07/louisiana-state-employees-retirement-system-has-970000-stake-in-quest-diagnostics-incorporated-nysedgx.html

Foster & Motley Inc. increased its holdings in shares of Quest Diagnostics Incorporated () by 2.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC.

Source: https://www.etfdailynews.com/2023/11/07/foster-motley-inc-has-5-59-million-position-in-quest-diagnostics-incorporated-nysedgx/

Mizuho reaffirmed a “buy” rating and set a $165.00 price target on shares of Quest Diagnostics in a research report on Friday, March 17th.

Source: https://www.americanbankingnews.com/2023/04/16/australiansuper-pty-ltd-reduces-holdings-in-quest-diagnostics-incorporated-nysedgx.html

Mizuho upped their target price on Quest Diagnostics from $160.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, December 14th.

Source: https://www.etfdailynews.com/2023/03/15/clearstead-advisors-llc-sells-1929-shares-of-quest-diagnostics-incorporated-nysedgx/

Piper Sandler increased their price target on shares of Quest Diagnostics from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Monday, November 6th.

Source: https://www.americanbankingnews.com/2023/12/10/quest-diagnostics-incorporated-nysedgx-shares-sold-by-state-street-corp.html

Piper Sandler initiated coverage on Quest Diagnostics in a research note on Thursday, June 29th.

Source: https://www.etfdailynews.com/2023/07/09/merit-financial-group-llc-has-874000-stake-in-quest-diagnostics-incorporated-nysedgx/

Quest Diagnostics declared that its Board of Directors has approved a share repurchase program on Thursday, February 2nd that allows the company to buyback $1.00 billion in shares.

Source: https://www.etfdailynews.com/2023/04/16/quest-diagnostics-incorporated-nysedgx-stake-boosted-by-new-york-state-common-retirement-fund/

Quest Diagnostics Incorporated has a 52 week low of $120.40 and a 52 week high of $158.34.

Source: https://www.americanbankingnews.com/2023/01/22/deseret-mutual-benefit-administrators-sells-209-shares-of-quest-diagnostics-incorporated-nysedgx.html

With processing at the Coombe currently paused, all CervicalCheck samples are being tested by Quest Diagnostics Inc. in the US.

Source: https://www.irishexaminer.com/news/arid-41105839.html